Published in Medical Letter on the CDC and FDA, October 29th, 2006
GAP is the largest study of its kind to evaluate patient adherence to long-term treatments for multiple sclerosis in a real-world setting with 176 sites across 22 countries participating. The cross-sectional observational study enrolled 2,566 patients with relapsing-remitting MS taking one of the DMTs.
Neurologists completed a practice-related...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA